Bicycle Therapeutics extends cash runway into 2030 after 30% job cuts
Biotech posts $48M Q4 revenue on Novartis/Bayer deal terminations, reprioritizes pipeline
Bicycle Therapeutics posted quarterly revenue of $48 million, handily beating analyst estimates of $7.4 million, driven by one-time recognition of collaboration revenue from terminated partnerships with Novartis and Bayer. The results, announced Tuesday alongside a sweeping corporate restructuring, sent shares up 5.7% to $5.05 in morning trading.
The Cambridge-based biotechnology company reported a net loss of $20.2 million for the fourth quarter of 2025, narrowing significantly from $51.9 million in the same period a year earlier. Earnings per share came in at negative 29 cents, exceeding analyst expectations of a $1.03 loss, according to MarketBeat earnings data.
The revenue surge—representing a 552% beat on Wall Street expectations—stemmed primarily from a $44.3 million increase in collaboration revenue. This jump reflected "the recognition of all remaining revenue from the collaboration agreement with Novartis Pharma AG upon termination, and revenue recognized from the termination of a program under the collaboration agreement with Bayer Consumer Care AG," according to company regulatory filings.
The deal terminations, while providing an immediate financial boost, prompted Bicycle Therapeutics to embark on a significant strategic overhaul. The company announced plans to reduce its workforce by approximately 30%, a move management said will extend its cash runway into 2030 based on current cash and cash equivalents of $628 million as of December 31, 2025.
Bicycle Therapeutics is reprioritizing its pipeline, deprioritizing internal development of zelenectide while converting its Duravelo-2 program to a randomized Phase 2 trial. The company will focus resources on BT5528 and next-generation Bicycle Radioconjugates (BRC®), areas where executives believe the technology platform holds the greatest commercial potential.
The restructuring comes as Bicycle Therapeutics grapples with the challenges typical of clinical-stage biotechnology companies—balancing limited cash resources against the high costs of drug development. With a market capitalization of $331.6 million and a 52-week trading range of $4.77 to $9.94, the company has faced pressure to demonstrate progress toward commercialization while preserving capital.
Analysts remain broadly optimistic about the company's long-term prospects despite the operational cuts. The stock carries an average rating of "Moderate Buy" from Wall Street, with 13 buy ratings and four hold ratings and no sell recommendations, according to MarketBeat analyst data.
The consensus 12-month price target stands at $19.63, implying upside of approximately 288% from current levels. Some analysts have issued even more aggressive near-term targets, with an average 30-day price target of $40.58 reported by StockScan.
Insider sentiment has been positive in recent weeks, with 15 different insiders purchasing shares, according to market data. This internal confidence contrasts with mixed short-term technical signals, which some analysts have labeled bearish while others see the stock as a "Strong Buy candidate" based on fundamental metrics.
Bicycle Therapeutics' proprietary Bicycle® platform creates synthetic molecules that combine the stability of small molecules with the specificity of antibodies. The technology is designed to target diseases that have proven difficult to treat with existing therapies, particularly in oncology.
The strategic pivot announced Tuesday represents a bet that concentrating resources on the most advanced programs will better position the company to advance its pipeline through clinical development while preserving enough capital to reach key value-inflection points. With cash now secured through the end of the decade, investors will be watching closely for clinical data readouts from the prioritized programs that could validate—or undermine—this high-stakes strategic bet.